Keros Therapeutics Inc. (KROS)
11.16
0.08 (0.72%)
At close: Mar 03, 2025, 12:31 PM
Keros Therapeutics Cash Flow Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -187.35M | -152.99M | -104.68M | -58.74M | -45.36M | -12.34M | -1.33M |
| Depreciation & Amortization | 1.23M | 815K | 674K | 378K | 278K | 208K | 153K |
| Stock-Based Compensation | 34.87M | 28.76M | 18.68M | 11.72M | 4.1M | 59K | 81K |
| Other Working Capital | -8.59M | 384K | -3.28M | -597K | 2.21M | -8.04M | 7.95M |
| Other Non-Cash Items | 1.82M | 1.56M | 953K | 520K | 1.82M | 2.79M | 194K |
| Deferred Income Tax | n/a | n/a | n/a | 46K | n/a | n/a | n/a |
| Change in Working Capital | -11.44M | -2.65M | 14.31M | -16.07M | 2.27M | -6.72M | 7.95M |
| Operating Cash Flow | -160.87M | -124.51M | -70.06M | -62.15M | -36.89M | -16M | 7.04M |
| Capital Expenditures | -1.93M | -2.46M | -1.24M | -1.02M | -294K | -271K | -217K |
| Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Investing Cash Flow | -1.93M | -2.46M | -1.24M | -1.02M | -294K | -271K | -217K |
| Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 11.69M | 3.13M | 731K | 379K | 52.84M | 14K | 11.46M |
| Financial Cash Flow | 391.82M | 178.96M | 120.31M | 28.55M | 296.04M | 14K | 11.46M |
| Net Cash Flow | 229.02M | 51.98M | 49.01M | -34.62M | 258.86M | -16.25M | 18.29M |
| Free Cash Flow | -162.8M | -126.97M | -71.3M | -63.17M | -37.19M | -16.27M | 6.83M |